$NVS News

Novartis signs $3.2bn drug delivery deal with Alteogen

Novartis stock rises after MS drug remibrutinib trial results

Novartis: Today's Positive Remibrutinib Data Key To Unlocking Growth Plans

The Multiple Sclerosis Drug Race Just Got Hotter After Novartis’ Phase 3 Win

Novartis (NYSE:NVS): A Dividend Quality Play for Income Investors

FDA Approval Nearly Doubles Eligible Patient Pool For Novartis' Pluvicto

Novartis (NYSE:NVS): A Top Dividend Stock with Strong Fundamentals and Sustainable Payouts

Novartis Q2 2026 Earnings Call Transcript

Novartis Silences Generic Fears With Blowout Quarter, Packed Pipeline

Novartis Reaffirms Low Single-Digit Net Sales Growth Guidance For 2026; Priority Brands Kisqali, Scemblix And Leqvio Post Strong Double-Digit Gains In Q2

Novartis Q2 Adj. EPS $2.41 Beats $2.13 Estimate, Sales $14.408B Beat $14.042B Estimate

This Novartis Drug Could Help Delay Dialysis—FDA Grants Full Approval

ARGUS RESEARCH CORPORATION Upgrades Novartis AG - Depositary Receipt (NVS)

Novartis AG Receives Health Canada Approval For Vanrafia To Reduce Preoteinuria Production In Immunoglobulin A Nephropathy Patients

NOVARTIS AG-SPONSORED ADR (NYSE:NVS): High-Quality Dividend Stock With Strong Profitability and Sustainable Payout

Novartis Scoops up UK Biotech Myricx in $1.5 Billion Cancer Push

Novartis Signs Agreement To Acquire Myricx Bio For $1.1B In Upfront Payment, $400M In Potential Milestone Payments

Novartis, Antares Partner To Pursue Undruggable Cancer Targets In $1.9 Billion Deal

Antares Therapeutics Partners With Novartis To Discover, Develop, Commercialize Small Molecule Therapies To Treat Undruggable Oncology Targets; Antares To Receive $105M Upfront Payment

Curium Prevails Patent Dispute Against Novartis Subsidiary Regarding Curium's Lutetium Lu 177 Dotatate Product; Court Claims Advanced Accelerator Applications' Claims Against Curium Invalid